Assertio Holdings, Inc. operates as a holding company. The firm develops pharmaceuticals. It engages in the provision of solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.
Company profile
Ticker
ASRT
Exchange
Website
CEO
Todd N. Smith
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Assertio Therapeutics, Inc, DEPOMED INC, DEPOMED INC
SEC CIK
Corporate docs
Subsidiaries
Assertio Therapeutics, Inc. • Depo DR Sub, LLC • Depo NF Sub, LLC • Assertio Management, LLC • Assertio Distribution, LLC • Alligator IP, LLC • Zyla Life Sciences, Inc. • Zyla Life Sciences US, Inc. • Egalet Limited • Otter Pharmaceuticals, LLC ...
IRS number
850598378
ASRT stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Assertio Reports Third Quarter 2022 Financial Results
8 Nov 22
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
Results of Operations and Financial Condition
8 Nov 22
8-K
Other Events
28 Oct 22
8-K
Assertio Announces Proposed Convertible Senior Notes Offering to Refinance Existing 13% Senior Secured Notes Due 2024
25 Aug 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
8-K
Assertio Reports Second Quarter 2022 Financial Results
8 Aug 22
UPLOAD
Letter from SEC
8 Jun 22
CORRESP
Correspondence with SEC
27 May 22
UPLOAD
Letter from SEC
16 May 22
Transcripts
ASRT
Earnings call transcript
2022 Q3
9 Nov 22
ASRT
Earnings call transcript
2022 Q2
8 Aug 22
ASRT
Earnings call transcript
2022 Q1
10 May 22
ASRT
Earnings call transcript
2021 Q4
9 Mar 22
ASRT
Earnings call transcript
2021 Q3
4 Nov 21
ASRT
Earnings call transcript
2021 Q2
6 Aug 21
ASRT
Earnings call transcript
2021 Q1
7 May 21
ASRT
Earnings call transcript
2020 Q4
12 Mar 21
ASRT
Earnings call transcript
2020 Q3
6 Nov 20
ASRT
Earnings call transcript
2020 Q2
7 Aug 20
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | |
|---|---|---|---|
| Revenue | |||
| Cost of revenue | |||
| Operating income | |||
| Operating margin | |||
| Net income | |||
| Net profit margin | |||
| Cash on hand | |||
| Change in cash | |||
| Diluted EPS |
Institutional ownership, Q3 2022
38.2% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 75 |
| Opened positions | 17 |
| Closed positions | 10 |
| Increased positions | 29 |
| Reduced positions | 8 |
| 13F shares | Current |
|---|---|
| Total value | 36.90 mm |
| Total shares | 18.46 mm |
| Total puts | 28.10 k |
| Total calls | 602.40 k |
| Total put/call ratio | 0.0 |
| Largest owners | Shares | Value |
|---|---|---|
| D. E. Shaw & Co | 2.32 mm | $830.00 k |
| Vanguard | 2.11 mm | $4.79 mm |
| Acadian Asset Management | 1.58 mm | $3.58 mm |
| Millennium Management | 1.05 mm | $2.38 mm |
| Littlejohn & Co | 945.68 k | $2.15 mm |
| BLK Blackrock | 892.24 k | $2.02 mm |
| Marshall Wace | 874.38 k | $1.99 mm |
| Bridgeway Capital Management | 795.80 k | $1.81 mm |
| Renaissance Technologies | 706.54 k | $1.60 mm |
| First Eagle Investment Management | 500.00 k | $1.14 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 Oct 22 | Sam Schlessinger | Common Stock | Payment of exercise | Dispose F | No | No | 0 | 7,205 | 0.00 | 33,597 |
| 1 Oct 22 | Sam Schlessinger | Common Stock | Option exercise | Acquire M | No | No | 0 | 19,404 | 0.00 | 40,802 |
| 1 Oct 22 | Sam Schlessinger | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 19,404 | 0.00 | 38,808 |
| 5 Aug 22 | Sam Schlessinger | Common Stock | Payment of exercise | Dispose F | No | No | 0 | 2,369 | 0.00 | 21,398 |
| 5 Aug 22 | Sam Schlessinger | Common Stock | Option exercise | Acquire M | No | No | 0 | 7,135 | 0.00 | 23,767 |
| 5 Aug 22 | Sam Schlessinger | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 7,135 | 0.00 | 7,135 |
| 31 Jul 22 | Ajay Patel | Common Stock | Payment of exercise | Dispose F | No | No | 0 | 3,157 | 0.00 | 57,681 |
| 31 Jul 22 | Ajay Patel | Common Stock | Option exercise | Acquire M | No | No | 0 | 8,060 | 0.00 | 60,838 |
| 31 Jul 22 | Ajay Patel | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 8,060 | 0.00 | 0 |
| 12 May 22 | Peisert Daniel A. | Stock Option Common Stock | Grant | Acquire A | No | No | 2.63 | 400,000 | 1.05 mm | 400,000 |
News
Assertio Announces Partnership With The Lennox-Gastaut Syndrome Foundation
17 Jan 23
12 Health Care Stocks Moving In Tuesday's After-Market Session
6 Dec 22
UPDATE: Assertio Therapeutics Q3 Adj. EPS $0.22 Beats $0.07 Estimate
8 Nov 22
Assertio Raises FY22 GAAP Sales From $129M-$137M To $141M+; Adjusted Non-GAAP EBITDA From $73M-$79M To $86M+
8 Nov 22
Earnings Scheduled For November 8, 2022
8 Nov 22
Press releases
Assertio Announces Partnership with the Lennox-Gastaut Syndrome (LGS) Foundation
17 Jan 23
Assertio Holdings, Inc. Announces FDA Orange Book Listing for New Sympazan® Oral Film Patent
9 Jan 23
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
6 Jan 23
Assertio Holdings, Inc. to Host Investor and Business Development Meetings January 9-11, 2023 in San Francisco
13 Dec 22
Assertio Increases Full-Year Net Product Sales Outlook to in Excess of $152 Million
5 Dec 22